# Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease

> **NCT03201445** · PHASE2 · TERMINATED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 139 (actual)

## Conditions studied

- Inflammatory Bowel Disease

## Interventions

- **DRUG:** Filgotinib
- **DRUG:** Placebo
- **DRUG:** Standard of Care

## Key facts

- **NCT ID:** NCT03201445
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-07-11
- **Primary completion:** 2020-11-20
- **Final completion:** 2023-10-24
- **Target enrollment:** 139 (ACTUAL)
- **Why stopped:** Early Termination for Reasons other than Safety
- **Last updated:** 2024-10-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03201445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03201445, "Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03201445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*